New pill tested for slowing diabetic kidney damage
NCT ID NCT06666283
Summary
This is an early-stage study to check the safety and how the body processes a new oral drug called AP303 in people with diabetic kidney disease. It will involve 18 participants who will take the drug or a placebo pill for two weeks. The main goal is to see how safe the drug is and how it behaves in the body, not to treat the disease at this stage.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
RECRUITINGBeijing, Beijing Municipality, 100009, China
Conditions
Explore the condition pages connected to this study.